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Abstract
The well-known reparative properties of mesenchymal stem cells (MSCs) 
make them an attractive source for cell-based therapy. In vitro and in vivo studies 
support an anti-inflammatory role of MSCs by directly targeting immune cells or 
via the secretion of immunomodulatory factors. MSCs have been isolated from 
several human normal tissues, even from pathological biopsies and blood samples; 
in these cases, MSCs displayed peculiar characteristics, suggesting a phenotype 
transition into a pathological state. Indeed, MSCs derived from inflamed tissues 
acquired a pro-inflammatory behaviour. In this view, MSCs may be crucial players 
of many pathways involved in human diseases, especially during the inflammatory 
cascade. The present chapter will minutely describe the basic biology of human 
MSCs derived from normal and pathological arteries, focusing on their dual nature 
as cellular switchers of the inflammatory setting. We will also discuss the emerging 
role of miRNAs in regulating MSC functions and their potential use as alternative 
strategies to manipulate MSC efficacy.
Keywords: mesenchymal stem cells (MSCs), immunomodulation,  
inflammatory process, phenotype switching, vascular wall
1. Introduction
Mesenchymal stem cells (MSCs) are adult, multipotent stem cells endowed of 
self-renewal, a process of continuous divisions essential to maintain the stem cell 
pool. Meanwhile, MSCs can be activated under the action of growth factors, chemo-
kines and cytokines which are normally released during the physiological tissue 
renewal or in pathological conditions in the presence of tissue damage. Specific 
signals stimulate the MSC migration at the damaged site and their differentiation 
into specialized cell types belonging to the mesodermal lineage. The homing and 
the differentiation potential allow MSCs to be actively involved in the tissue homeo-
stasis as well as in the repair process. MSCs have been firstly identified as a non-
hematopoietic, adherent and spindle-shaped cell subset of the human bone marrow 
stroma [1]. From their first isolation in 1970, MSCs have been extensively character-
ized, gaining the increasing interest of the scientific community, and lots of studies 
issued the biology and the inner properties of these promising cells. One of the 
most intriguing and studied functions of MSCs is the immunomodulation, that is, 
the ability to repress inflammation; however, little is known about the reversal of 
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this property that has been observed in some disease models. The present chapter 
will review the differentiation and immunomodulatory capabilities of MSCs, will 
discuss the contradictory face of MSCs and will focus on the vascular wall setting.
2. Mesenchymal stem cells (MSCs): source, phenotype and properties
In vivo and in vitro data have demonstrated the unique reparative potential of 
MSCs, which are now considered as the most attractive and functional source for 
cell-based therapies in the field of regenerative medicine. First of all, the ease of 
MSC isolation and in vitro propagation excited researchers, who addressed their 
efforts to find novel sources for MSCs and to characterize them. MSCs have been 
efficiently isolated and characterized from different human tissues, other than 
their native site, i.e. peripheral blood [2], umbilical cord (UC) blood [3], fat [4], 
Wharton’s jelly (WJ) [5], synovial membrane [6] and vascular wall [7, 8]. The lack 
of standard markers, differences in laboratory procedures, type and age of the 
source tissue may affect the purity of MSC pool and impair their effectiveness for 
clinical applications. In order to fill this gap and provide a consensus statement for 
MSC definition, the International Society for Cellular Therapy (ISCT) postulated 
the following minimal criteria [9]:
• Adherence to plastic substrate in vitro
• Expression of surface markers CD90, CD105 and CD73 (mesenchymal linage) 
and lack of CD34, CD19, CD45 and CD11a (hematopoietic lineage), CD31 
(endothelial lineage) and HLA-DR (human leukocyte antigen)
• Multilineage differentiation ability into the mesodermal lineage (chondro-
genic, adipogenic, osteogenic commitments)
Even if researchers concur with the consideration of CD34 as distinctive marker of 
endothelial and hematopoietic cells, it has been detected also in MSCs correlating with 
advanced progenitor properties [10, 11]. Moreover, adipose tissue-derived MSCs posi-
tive to CD34 lost its expression after in vitro propagation suggesting that the absence 
of CD34 may be a result of in vitro culture [12, 13]. Thus, the immunophenotype is not 
per se sufficient to identify MSCs, but functional assays aimed at testing the stemness 
properties, like the ability to form colonies, and the differentiation potential are neces-
sary. At this regard, MSCs also manifest the capacity to differentiate into ectoderm- 
and endoderm-derived cell types, i.e. endothelial cells, neurons and hepatocytes.
The presence of MSCs with self-renewal and multilineage differentiation prop-
erties within adult tissues suggests their intrinsic participation to the regular tissue 
homeostasis and cell turnover. Cytokines and chemokines that are released from 
the injured tissue act as recruiting factors of MSCs from their niche, allowing their 
mobilization and trafficking. The ability of differentiate into tissue-specific cell 
types is the major mechanism through which MSCs replace dead cells; in addition, 
MSCs secrete soluble factors that include hepatocyte growth factor (HGF), trans-
forming growth factor (TGF) β1 and vascular endothelial growth factor (VEGF) 
and contribute to cutaneous wound healing [14].
The migration and the differentiation abilities support the clinical use of MSCs 
for the cure of degenerative diseases but, if uncontrolled or impaired, could become 
prerequisites to the occurrence of pathological conditions. Further, the tissue source 
constitutes a discriminating factor among MSCs in terms of differentiation potency, 
migration and effectiveness in tissue repair. The differentiation potency can also 
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be regulated on epigenetic basis; at this regard, the methylation status of the main 
regulators of MSC fate crucially drives the differentiation program. This condition 
has been demonstrated in a study by Xu et al., where BM-MSCs resulted more effec-
tive in osteogenic differentiation than adipose tissue (AT)-MSCs, which displayed 
the opposite trend and were mainly addressed towards the adipogenic commitment 
[15]. Similarly, perivascular MSCs isolated from the UC blood exhibited higher 
angiogenic potency than umbilical artery and WJ- MSCs, with implications for the 
cure of ischemic injury [16]. Therefore, the clinical use of MSCs is a promising and 
undeniable chance for regenerative medicine, but it needs to be optimized because 
of the MSC multifaceted nature
2.1 MSC immunomodulation
A large body of experimental and clinical studies showed that MSCs modulate 
the immune response, both innate and adaptive with possible implications in the 
management of transplantation, autoimmune and inflammatory disorders [17]. 
MSCs have been historically considered as immune-privileged cells, because of their 
poor immunogenicity. Indeed, the low levels of human leukocyte antigen (HLA) 
histocompatibility complex-I and the lack the complex HLA-II allow MSCs to elicit 
the immune recognition. Additionally, MSCs do not express the Fas ligand and the 
co-stimulatory molecules CD40, CD80 (B7-1) and CD86 (B7-2), which are neces-
sary for effector T-cell activation [18, 19]. On the other hand, it has been widely 
demonstrated that MSCs affect the immune system, both through cell–cell interac-
tions and by the paracrine secretion of anti-inflammatory factors.
2.2 MSC-immune cell interactions and in vitro immunomodulatory assays
The majority of studies use a mixed lymphocyte reaction (MLR) assay and 
explore the immunosuppressive effects of MSCs on allogeneic T cells in the MLR 
reaction. Peripheral blood mononuclear cells (PBMCs) are obtained by density 
gradient separation and cultured on a feeder layer of irradiated MSCs generally for 
3 or 5 days. PBMCs are stimulated by the addition of mitogens to the culture media 
like phytohaemagglutinin (PHA), which markedly induces CD8 T-cell proliferation 
[20]. The coculture protocol can be executed in a direct manner for testing effects 
mediated by physical cell-cell interactions; alternatively, it is possible to evaluate the 
influence of MSC paracrine secretion in a separate coculture system by the use of a 
Transwell insert of 0.4 μm that inhibits PBMC migration and maintains the two cell 
compartments separated. At the end of the experimental coculture, PBMCs are col-
lected and analyzed in terms of proliferation and activation. Cell cycle analysis and 
specific proliferation test, like the incorporation rate of bromodeoxyuridine (BrdU) 
into DNA, are executed for T-cell survival together with the analysis of T-cell 
subpopulation percentage. On the other hand, MSCs are characterized for immuno-
modulatory markers, such as HLA-G, interleukin (IL)-10 and HGF, through a wide 
range of techniques including flow cytometry, immunofluorescence and Western 
blot. A pictorial description of the basic immunomodulatory assay can be observed 
in Figure 1a. MSCs inhibit naïve CD4+ T helper cell proliferation by inducing the 
cell cycle arrest at G0 and by hindering the T helper cell differentiation into TH1 and 
TH17 subsets. In addition to direct cell-cell interactions, the MSC immunomodula-
tion is exerted through the secretion of soluble anti-inflammatory mediators, such 
as nitric oxide (NO), TGF-β1, interleukin (IL)-10, indoleamine 2,3-dioxygenase 
(IDO), HGF and prostaglandin E2 (PGE2). HLA-G is another crucial component 
involved into the MSC immunosuppressive system, allowing the induction of 
regulatory T cells (Treg) and inhibiting natural killer (NK) cell cytotoxicity and 
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dendritic cell (DC) maturation [21, 22]. MSCs further exert their immunosuppres-
sive effects on B cells, blocking their proliferation. The scheme in Figure 1b sum-
marizes the main mechanisms relative to the MSC-driven immunomodulation.
The successful application of MSCs has been reported in several clinical studies; 
among these, MSCs resulted effective in graft-versus-host disease (GvHD) patients 
even in those resistant to steroid treatment. Moreover, beneficial effects were observed 
in patients affected by systemic lupus erythematous (SLE) and Crohn’s disease [23].
Figure 1. 
MSC immunomodulation: (a) schematic description of the immunomodulatory procedure for testing the MSC 
effects on PBMCs; and (b) overview of the main mechanisms MSC-dependent on immune cells. Abbreviations: 
PBMC, peripheral blood mononuclear cells; PHA, phytohaemagglutinin; HLA-G, human leukocyte antigen; 
HGF, hepatocyte growth factor; TGF-β1, transforming growth factor; IL-10, interleukin; NO, nitric oxide; 
IDO, indoleamine 2,3-dioxygenase; PGE2, prostaglandin E2.
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However, the effectiveness and safety of MSC application are still under debate, 
and some data suggest that the immunomodulatory function is tightly regulated. 
Moreover, many studies have elucidated differences in terms of immunomodula-
tory potency among MSCs isolated from distinct sources. At this regard, a study by 
Mattar et al. compared the immunosuppressive properties of BM-MSCs, AT-MSCs, 
CB-MSCs and WJ-MSCs on PHA-activated T cells, showing that MSCs from tissues 
alternative to bone marrow were effective in inhibiting T-cell proliferation [24]. 
Similarly, Li et al. demonstrated that WJ-MSCs exhibited the highest immuno-
suppressive force and lowest levels of immunogenic factors than AT-, BM- and 
PL-MSCs, thus resulting as the most promising for potential therapeutic application 
[25, 26]. Further comparative analysis aimed at deepen functional characteristics of 
MSCs from multiple sources is necessary to improve their translation into the clinic.
2.3 MSCs like macrophages: switch from pro-inflammatory to  
anti-inflammatory phenotype
Several studies have addressed the intrinsic mechanisms associated with MSC 
immunomodulation, and increasingly evidences have demonstrated the plastic 
nature of this intriguing property. The effectiveness of MSC immunomodulation can 
depend on the external microenvironment; different studies support the hypothesis 
that MSCs can both reduce and strengthen the inflammatory process but is the 
inflammatory context itself at determining the immunosuppressive function of 
MSCs. Thus, MSCs need to be ‘licensed’ for their activation and regulate the immune 
response [23]. At this regard, MSCs can switch from a pro-inflammatory to an anti-
inflammatory phenotype, characterized by a different soluble factor and cytokine 
panel. This paradigm mimics the macrophage polarization model. Macrophages are 
immune cells that derive from the differentiation of their precursor cells, mono-
cytes, and represent key players of the immune response. Monocytes, once arrived at 
the damaged site, can differentiate into M1- or M2-type macrophage, depending on 
the microenvironment stimuli. The M1 macrophage releases a series of inflammatory 
cytokines, contributing to the local inflammation; conversely, the M2 macrophage 
mainly secretes IL-10 and TGF-β1 that are anti-inflammatory. The local microen-
vironment critically triggers MSC polarization, and the Toll-like receptors (TLRs) 
are of crucial importance in this regulatory mechanism. TLRs represent a conserved 
family of pattern recognition receptors (PRRs) able to detect a wide spectrum of 
pathogen-associated patterns (PAMPs) and activate the immune cells. The expres-
sion of TLRs in MSCs changes according to the tissue source but also depends on the 
microenvironment stimuli. According to Bunnel et al., the activation of TLR4 trig-
gers MSCs skew into a pro-inflammatory phenotype, releasing factors like IL-6 and 
IL-8 that contribute to tissue injury [27]. Conversely, the stimulation of TLR3 shifts 
MSCs to the anti-inflammatory phenotype accompanied by the secretion of IL-4, 
IDO and PGE-2 [27, 28]. Other studies support the contribution of nitric oxide (NO) 
to the anti-inflammatory activity of MSCs; indeed, the inhibition or the genetic 
ablation of NO synthase (iNOS) stimulates T-cell proliferation after being cultured 
with MSCs [29]. Thus, the poor activation of MSC anti-inflammatory profile leads 
to the worsening of the inflammatory process and of the tissue damage. Defects 
of the immunomodulatory functions have been observed in some diseases, like a 
study on a mouse model of collagen-induced arthritis (CIA) demonstrated. MSCs 
exposed to an inflammatory environment, like in the CIA model, displayed impaired 
immunomodulation and, after TNF-α addition, lost the ability to regulate T-cell 
proliferation [30]. Also, MSCs isolated from the bone marrow of multiple myeloma 
patients were ineffective in vitro, reflecting an aberrant T-cell function in vivo 
[31]. The therapeutic application of MSCs for treating inflammatory conditions is 
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really promising; nevertheless, the effectiveness and safety of their administration 
in vivo are still controversial, representing a challenging issue. The diversity of MSC 
biology and mechanism of action implicate knowledge gaps that need to be filled for 
a clinical application of MSCs on large scale [32, 33]. For this reason, novel studies 
should address all the technical concerns related to the use of MSCs and extend their 
investigation field to MSCs from human disease models.
3. Tissue specificity of MSCs: normal versus diseased arteries
As described in the second paragraph, MSCs are markedly represented in several 
adult human tissues other than bone marrow and fat; the rationale to this wide 
distribution comes from the existence of the vasculogenic zone, which is a stem cell 
niche within the vascular wall.
In this field, our research team has reached a 10-year experience in isolating MSCs 
from a broad range of vascular segments of small and large size, including healthy 
and diseased arteries. As regards the technical concerns, the isolation protocol 
consists of the enzymatic digestion of both fresh and cryopreserved arteries collected 
at the Cardiovascular Tissue and Cord Blood Bank (S. Orsola-Malpighi Hospital, 
Bologna, Emilia Romagna-Italy) and belonged to different vascular districts (carotid 
bifurcation, aortic arch, abdominal/thoracic aorta, femoral artery). In spite of 
the extreme temperature conservation in liquid nitrogen for about 10 years, these 
vascular tissues were vital and resulted as an unusual source of clonogenic and highly 
proliferative MSCs endowed of chondrogenic, adipogenic, osteogenic and smooth 
muscle differentiation capability [34]. Interestingly, these human vascular wall-
MSCs (hVW-MSCs) possess angiogenic potential, as demonstrated by the capacity 
of forming a capillary-like network when seeded onto a semi-solid matrix (Matrigel) 
and by the expression of endothelial markers after VEGF stimulation. The capacity 
of VW-MSCs to differentiate into endothelial-like cells befits with their location 
within the arterial wall, suggesting their function as cell reservoir during the normal 
tissue renewal. The angiogenic potential and the migratory capacity of VW-MSCs 
were explored as crucial aspects for the healing of vascular ulcers and resulted 
boosted under the effects of recombinant HGF [35]. Another intriguing finding sup-
porting the therapeutic force of VW-MSCs regarded the immunomodulatory capa-
bility. The vessel wall is prone to inflammatory infiltration following the endothelial 
dysfunction; thus, it is reasonable to hypothesize that vascular resident progenitors 
are able to contain this phenomenon. hVW-MSCs exerted a significant suppressive 
effect on PHA-PBMCs proliferation, partially mediated by the expression of HLA-
G. These data support the existence of MSC cells within the vascular wall and their 
participation in the normal tissue homeostasis as well as in the arterial repair. During 
the early phase of the atherogenic process, monocytes cross the endothelial barrier 
and differentiate into macrophages within the media where the release of matrix 
metalloproteinases (MMPs), cytokines and chemokines recruits other monocytes 
and lymphocytes. This vascular inflammation is the licencing factor that activates 
vascular MSCs into the immunosuppressive phenotype; any intimate disturbance to 
this mechanism may skew MSCs into the opposite trend, failing in vascular healing.
3.1 Functional deregulation of MSCs within the injured artery
As reported in some disease models, like osteo-chondrogenic disorders or hema-
tological affections, MSCs can undergo a deregulation of their reparative properties 
that can be enhanced or defected with undeniable pathological implications. Our 
team investigated the contradictory face of MSCs, extending the analysis to the field 
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of cardiovascular diseases like abdominal aortic aneurysm (AAA), atherosclerotic 
carotid plaque and arteriovenous fistula. AAA is a chronic dilatation of the aortic wall, 
due to the exaggerated degradation of extracellular matrix proteins by MMPs result-
ing in the loss of elastin and collagen; in addition, the inflammatory infiltrate occurs 
and contributes to the degeneration of the media tunica, together with further release 
of MMPs and the destabilization of the wall. Published data have shown for the first 
time that, in spite of the complete disorganization of the tissue, MSCs isolated from 
the AAA wall (named AAA-MSCs) were comparable to the healthy counterpart in 
morphology, growth rate and immunophenotype [36]. Even more, these pathological 
MSCs displayed altered functions in vitro; consistent with the chronic inflammatory 
setting of the AAA disease, AAA-MSCs displayed low HLA-G expression and resulted 
ineffective in modulating the PBMC proliferation. This low efficacy may reflect the 
switch of vascular MSCs into the pro-inflammatory phenotype and the worsening 
of the aortic wall conditions. Angiogenesis represents another distinctive hallmark 
of AAA pathology, significantly affecting the wall stability. AAA-MSCs were able to 
differentiate into endothelial-like cells, as demonstrated by the formation of a vas-
cular network onto Matrigel and by the positivity to CD31 marker. Nevertheless, we 
observed a reduced expression of CD146, a pericyte marker, suggesting the instability 
and immaturity of the AAA-MSC-derived neo-vessels [37]. A representative image of 
AAA-MSC functional characteristics is reported in Figure 2.
Other few works have issued the pathological role of MSCs residing within 
the vasculogenic zone. At this regard, the first hypothesis on MSC contribution 
to vascular diseases was proposed in 2012 by Tang et al., who showed that rodent 
MSCs undergo increased proliferation and migration upon vascular injury [38]. In 
2016, a study of Kramann et al. performed on ApoE−/− mice with chronic kidney 
disease demonstrated the involvement of a population of MSC-like cells to the onset 
of athero- and arteriosclerosis as well as to the differentiation into osteoblast-like 
cells [39]. An aberrant differentiation program of MSCs can be crucial in trigger-
ing the complications of the atherosclerotic plaque, like ectopic bone formation, 
Figure 2. 
Immunophenotype and differentiation assays of AAA-MSCs: (a) AAA-MSCs positive to CD90, CD44, CD73, CD105 
and MMP-9 and negative to CD45 and CD34 were isolated from the aorta affected by aneurysm, inflammation 
and atherosclerotic plaque. (b) AAA-MSCs were characterized for adipogenic, osteogenic, chondrogenic and  
endothelial differentiation abilities. Abbreviations: HLA, human leukocyte antigen; MMP, matrix 
metalloproteinase; PPAR, peroxisome proliferator-activated receptor; BMP, bone morphogenetic protein; OPN, 
osteopontin; CII, collagen type 2; SMA, smooth muscle actin.
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and represents the early stage during calcification process [40]. AAA-MSCs also 
exhibited a marked osteogenic ability, correlating with the vascular calcium levels 
as measured by angio-CT in the enrolled patients [37]. Thus, it can be postulated 
that MSCs are key players during the renewal as well as the pathological conditions 
affecting the vascular wall. The MSC behaviour can be seen as fine balance between 
two opposite forces, which is strongly influenced by the external microenvironment 
and the interaction with the neighboring cells. At this regard, the immune cells 
and the cytokines released during inflammation are key factors in exacerbating the 
osteogenic differentiation of healthy VW-MSCs [37].
The most remarkable characteristics of AAA-MSCs and their comparison to the 
hVW-MSCs are summarized in Table 1.
4. miRNA regulation of MSC immunomodulatory capacity
Micro-RNAs (miRNAs) constitute a class of single-stranded non-coding RNAs 
of approximately 18–22 nucleotides that function as endogenous regulators of 
gene expression through the degradation of the target mRNA or the inhibition of 
the transcription process. Over the last decade, the growing interest for miRNA 
applications elucidated their involvement into many biological mechanisms, like cell 
growth and proliferation. Based on the observation that miRNAs are differentially 
regulated in the presence of pathological conditions like cancer or immune diseases, 
many researchers have proposed their use as diagnostic markers or therapeutic 
targets. Several studies revealed the miRNA involvement into the hematopoietic 
stem cell (HSC) system, driving aspects like cell survival, self-renewal and differ-
entiation. Moreover, these ‘immuno-miRs’ orchestrate crucial steps of both innate 
and adaptive immune cell development and function [41]. miR-21, miR-146a and 
miR-155 are included in this category and are induced upon T-cell receptor (TCR) 
Table 1. 
Phenotypic and functional characteristics of healthy versus pathological vascular MSCs.
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activation through the NF-kB cascade. miRNAs have also been shown to regulate 
the stem cell behaviour, self-renewal and differentiation; therefore, investigating 
immuno-miRs in human MSCs could be suggestive of their reparative proper-
ties like differentiation and immunomodulatory potency. Some of the described 
immuno-miRs target the TLR pathway in MSCs or immune cells suppressing or 
enhancing TLR activation by targeting adapter molecules, cytokines and transcrip-
tion factors. At this regard, a work by Matysiak et al. demonstrated the upregulation 
of several miRNAs in differentiated BMSCs that had lost immunomodulation, 
including miR-146a, together with a low expression of PGE2 [42]. The role of miR-
155 in interfering with MSC immunomodulation has been also reported; indeed, 
miR-155 decreases the iNOS production in cytokine-activated MSCs, partially 
targeting TGF-beta-activated kinase 2 (TAB2), an adapter protein involved in 
TLR pathways [43]. As recently demonstrated, many of the therapeutic effects of 
MSCs are mediated by the extracellular vesicles (EVs), which are membrane-bound 
vesicles that serve as vehicle of mRNAs and proteins. Moreover, EVs are enriched of 
miRNAs that are released in the circulatory system. The EV-released miRNAs, such 
as Let-7b, miR-1180 and miR-183, induce macrophage polarization into M2 pheno-
type and mitigate inflammation by reducing TLR4 [44]. The mechanisms regulating 
the miRNA-MSCs interplay are complex and require further investigations; the use 
of miRNA-enriched EVs derived from human MSCs could be the promising thera-
peutic cell-free alternative for the cure of GvHD and inflammatory diseases.
5. Conclusions
The regenerative and reparative properties of MSCs are certainly undisguised 
even though many efforts are necessary to ensure their use for clinical therapy. The 
contradictory inflammatory activity of MSCs is a result of their plastic nature and 
represents a critical issue that needs to be addressed. Tissue-resident MSCs can rep-
resent the optimal target of stem cell-reprogramming therapies aimed at restoring 
their native reparative properties. The emerging role of miRNAs in regulating the 
MSC functions is promising and requires further investigations for miRNA manipu-
lation in order to address MSC towards a more efficient and safe reparative activity.
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